...
首页> 外文期刊>Journal of Clinical Microbiology >High-Resolution Melting Approach to Efficient Identification and Quantification of H275Y Mutant Influenza H1N1/2009 Virus in Mixed-Virus-Population Samples
【24h】

High-Resolution Melting Approach to Efficient Identification and Quantification of H275Y Mutant Influenza H1N1/2009 Virus in Mixed-Virus-Population Samples

机译:高效融解方法可有效鉴定和定量混合人群中的H275Y突变型H1N1 / 2009病毒

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The single-nucleotide variation 823C to T (His275Tyr), responsible for oseltamivir drug resistance has been detected in some isolates of the influenza A/H1N1/2009 virus. Early detection of the presence of this oseltamivir-resistant strain allows prompt consideration of alternative treatment options. An isolated-probe–asymmetric amplification PCR (Roche LightCycler v2.0) and high-resolution melting (HRM) method using unlabeled probes and amplified products (Idaho LightScanner 32) was designed and optimized to detect and estimate the proportion of H275Y mutants in influenza A/H1N1/2009 virus samples. The lower limit of quantification within the linear range of PCR assay detection was 200 copies/reaction. The melting peaks of the H275Y-specific unlabeled probe for the wild-type A/H1N1/2009 and H275Y mutant viruses were clearly distinguishable at 65.5°C and 69.0°C, respectively, at various ratios of wild-type/mutant virus population standards. The 95% detection limit for the 10% mutant sample pool was 1,200 copies/reaction (95% confidence interval, 669.7 to 3,032.6 copies/reaction). This HRM assay was tested with 116 archived clinical specimens. The quantitative HRM results obtained with samples containing mixed mutant–wild-type virus populations, at threshold cycle (CT) values of <29, compared well to those obtained with a pyrosequencing method performed by an independent laboratory. The quantitative feature of this assay allows the proportions of mutant and wild-type viral populations to be determined, which may assist in the conventional clinical management of infected patients and potentially more preemptive clinical management. This validated quantitative HRM method, with its low running cost, is well positioned as a rapid, high-throughput screening tool for oseltamivir resistance mutations in influenza A/H1N1/2009 virus-infected patients, with the potential to be adapted to other influenza virus species.
机译:在A / H1N1 / 2009流感病毒的某些分离株中已检测到负责oseltamivir耐药的单核苷酸变体823C至T(His275Tyr)。及早发现这种耐奥司他韦的菌株可迅速考虑其他治疗方案。设计并优化了分离探针-不对称扩增PCR(Roche LightCycler v2.0)和使用未标记探针和扩增产物(Idaho LightScanner 32)的高分辨率解链(HRM)方法,以检测和评估流感病毒中H275Y突变体的比例A / H1N1 / 2009病毒样本。 PCR分析检测的线性范围内的定量下限为200拷贝/反应。野生型A / H1N1 / 2009和H275Y突变型病毒的H275Y特异性未标记探针的熔解峰在不同比例的野生型/突变型病毒种群标准下分别在65.5°C和69.0°C时清晰可见。 10%突变样品池的95%检测极限为1,200拷贝/反应(95%置信区间,669.7至3,032.6拷贝/反应)。使用116个存档的临床标本对HRM分析进行了测试。与阈值循环( C T )的阈值循环( C T )值相比,使用包含突变的野生型病毒混合种群的样品获得的定量HRM结果与使用由独立实验室进行的焦磷酸测序方法。该测定的定量特征允许确定突变型和野生型病毒种群的比例,这可以有助于感染患者的常规临床管理以及潜在的更先发性的临床管理。这种经过验证的定量HRM方法具有较低的运行成本,非常适合作为A / H1N1 / 2009流感病毒感染患者的oseltamivir耐药突变的快速,高通量筛选工具,并有可能适应其他流感病毒种类。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号